| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | IHC:1/100-1/200;IHF:1/50-1/200 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/20-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CPD6; CYP2D; CYP2D6; CYP2D7AP; CYP2D7BP; CYP2D7P2; CYP2D8P2; CYP2DL1; CYPIID6; P450 DB1; P450C2D; P450DB1; Xenobiotic monooxygenase;;Cytochrome P450 2D6 |
| WB Predicted band size | Calculated MW: 56 kDa ; Observed MW: 50,55,80 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human Cytochrome P450 2D6 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于Cytochrome P450 2D6(CYP2D6)抗体的3篇参考文献摘要：
---
1. **文献名称**: "Production and characterization of monoclonal antibodies against human cytochrome P450 2D6"
**作者**: Zanger, U.M., et al.
**摘要**: 该研究报道了针对人CYP2D6的单克隆抗体制备及特性分析。抗体通过免疫小鼠获得，经Western blot和免疫组化验证其特异性，可用于检测肝微粒体及细胞中CYP2D6的蛋白表达水平，为代谢表型分型提供工具。
---
2. **文献名称**: "CYP2D6 genotyping and phenotyping: focus on antibody-based methods"
**作者**: Hicks, J.K., et al.
**摘要**: 文章综述了CYP2D6基因多态性对药物代谢的影响，并比较了基于抗体的免疫分析法(如ELISA)与基因分型技术的优缺点。研究强调抗体在快速检测CYP2D6酶表达量及活性中的应用价值。
---
3. **文献名称**: "Immunoquantification of cytochrome P450 2D6 in hepatic microsomes: a tool for personalized medicine"
**作者**: Matsunaga, M., et al.
**摘要**: 该研究开发了一种基于抗体的定量检测方法，用于测定肝微粒体中CYP2D6的蛋白浓度。通过对比不同代谢表型个体的样本，证明抗体检测结果与酶活性高度相关，支持其在个体化用药中的临床应用。
---
如需更多文献，可进一步补充!
Cytochrome P450 2D6 (CYP2D6) is a member of the cytochrome P450 enzyme superfamily, primarily expressed in the liver and involved in the metabolism of approximately 25% of clinically used drugs, including antidepressants, antipsychotics, beta-blockers, and opioids. CYP2D6 exhibits significant genetic polymorphism, with over 100 allelic variants identified, leading to variable enzyme activity categorized into ultrarapid (UM), extensive (EM), intermediate (IM), and poor metabolizer (PM) phenotypes. These variations influence drug efficacy, toxicity, and individual responses to medications.
CYP2D6 antibodies are immunological tools designed to detect and quantify the expression of the CYP2D6 protein in research and diagnostic settings. They are commonly used in techniques like Western blotting, immunohistochemistry (IHC), and enzyme-linked immunosorbent assays (ELISA) to study tissue-specific expression, genetic regulation, or drug-induced changes in enzyme levels. Such antibodies aid in correlating genotype-phenotype relationships, particularly in pharmacogenomic studies, where understanding CYP2D6 activity is critical for personalized medicine.
Commercially available CYP2D6 antibodies are typically raised against specific epitopes of the human enzyme, ensuring specificity for targeted assays. However, cross-reactivity with related cytochrome isoforms or species homologs requires careful validation. Research utilizing these antibodies has advanced insights into drug metabolism, drug-drug interactions, and the role of CYP2D6 in diseases, including cancer and neurological disorders. Their application supports both clinical diagnostics and the development of tailored therapeutic strategies.
×
